Providers can prescribe anti-nausea medication, adjust your dose, slow escalation, or provide management strategies
However, early evidence suggests the weight loss achieved stays stable when treatment continues
What's New: August 2026 Update TRIUMPH-2 confirmed (July 23, 2026): Obesity + type 2 diabetes trial, 1,152 patients up to 20.8% weight loss and up to 1.6 percentage points HbA1c reduction at 80 weeks TRIUMPH-3 confirmed (July 23, 2026): Obesity + established cardiovascular disease trial, 1,949 patients up to 22.6% weight loss at 80 weeks, plus significant improvements in triglycerides, blood pressure, and inflammatory markers All four core TRIUMPH registrational trials are now complete TRIUMPH-1, TRIUMPH-2, TRIUMPH-3, and TRIUMPH-4 have all reported positive topline results TRIUMPH-4 confirmed final: 28.7% weight loss at 68 weeks topline results announced December 2025 TRIUMPH-1 confirmed (May 21, 2026): 28.3% average weight loss at 80 weeks in 2,339 patients
Markkinoitavia valmisteita on monia, ja ne saattavat aiheuttaa hmmennyst
April 16, 2025: Parties in Trulicity Lawsuit to Hold Hearing on Gastroparesis On May 14, 2025, the parties involved in the Trulicity multidistrict litigation will hold a hearing about the reliable diagnostic process for gastroparesis